KR920703512A - 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논 - Google Patents

단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논

Info

Publication number
KR920703512A
KR920703512A KR1019920701571A KR920701571A KR920703512A KR 920703512 A KR920703512 A KR 920703512A KR 1019920701571 A KR1019920701571 A KR 1019920701571A KR 920701571 A KR920701571 A KR 920701571A KR 920703512 A KR920703512 A KR 920703512A
Authority
KR
South Korea
Prior art keywords
independently
aryl
compound
alkyl
arylalkyl
Prior art date
Application number
KR1019920701571A
Other languages
English (en)
Inventor
비이. 지앙 잭
조지 존슨 매리
Original Assignee
클레이턴 아이. 던칸
스핑크스 파마슈티칼스, 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클레이턴 아이. 던칸, 스핑크스 파마슈티칼스, 코포레이션 filed Critical 클레이턴 아이. 던칸
Publication of KR920703512A publication Critical patent/KR920703512A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/32—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by at least three rings
    • C07C225/34—Amino anthraquinones
    • C07C225/36—Amino anthraquinones the carbon skeleton being further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/32—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by at least three rings
    • C07C225/34—Amino anthraquinones

Abstract

내용 없음

Description

단백질 활성효소 C(PROTEIN KINASE C)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논
[도면의 간단한 설명]
제1도는 본 발명의 화합물의 합성에 이용되는 도표 I의 합성 루트를 보여준다.
제2도는 본 발명의 화합물이 합성에 이용되는 도표 II의 합성 루트를 보여준다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 하기의 식을 가지는 치환 안트라퀴논
    식에서, R1과 R2는 독립적으로 H, 알킬, 아릴 또는 아릴알킬; m과 n은 독립적인 1,2 또는 3; X는 H, OH, NR3R4, Cl, Br, I, F, 알킬, 아릴 알콕시, 아록시, COOR5, 또는 CONR6R7; 그리고 R3, R4, R5, R6및 R7은 독립적으로 H, 저가 알킬 또는 아릴인 것을 특징으로 하는 치환 안트라퀴논.
  2. 제1항에 있어서, R1과 R2는 독립적으로 H저가 알킬, 또는 아릴알킬; m과 n은 독립적인 1, 또는 2; X는 H, OH, Cl, Br, I, F, 알콕시인 것을 특징으로 하는 치환 안트라퀴논.
  3. 제2항에 있어서, R1과 R2는 독립적으로 H, 또는 아릴알킬; m과 n는 1;X는 H, OH인 것을 특징으로 하는 치환 안트라퀴논.
  4. 제1항의 치환된 안트라퀴논으로 구성되는 단백질 활성효소 C를 방해하는 약제적 조성물과 약제적으로 수용가능한 운반체 또는 희석제.
  5. 제2항의 치환된 안트라퀴논으로 구성되는 단백질 활성효소 C를 방해하는 약제적 조성물과 약제적으로 수용가능한 운반체 또는 희석제.
  6. 제3항의 치환된 안트라퀴논으로 구성되는 단백질 활성효소 C를 방해하는 약제학적 조성물파 약제학적 수용가능한 운반체 또는 희석제.
  7. 하기 식의 화합물을 이용하여
    식에서 R1과 R2는 독립적으로 H, 알킬, 아릴 또는 아릴알킬; m과 n은 독립적인 1,2 또는 3; X는 H, OH, NR3R4, Cl, Br, I, F, 알킬, 아릴 알콕시, 아록시, COOR5, 또는 CONR6R7; 그리고 R3, R4, R5, R6및 R7은 독립적으로 단백질 활성효소 C방해용의 약제 준비에서 H, 저가 알킬 또는 아릴을 이용하는 것을 특징으로 하는 치환 안트라퀴논.
  8. 제7항에 있어서, 상기한 식의 화합물의 R1과 R2는 독립적으로 H, 저가 알킬, 또는 아릴알킬; m과 n은 독립적인 1, 또는 2: X는 H, OH, Cl, Br, I, F, 알콕시를 이용하는 것을 특징으로 하는 치환 안트라퀴논.
  9. 제8항에 있어서, 상기한 식의 화합물의 R1과 R2는 독립적으로 H, 또는 아릴알킬; m과 n은 1;X는 H, 또는 OH를 이용하는 것을 특징으로 하는 치환 안트라퀴논.
  10. 제7항에 있어서, 상기한 화합물은 약제학적으로 효과적인 양으로 상기 약제 내에 존재하는 것을 특징으로 하는 치환 안트라퀴논.
  11. 하기식으로 이루어지는 치환된 안트라퀴논의 방해량을 가지는 단백질 활성효소 C와 접촉하는 것으로 구성된 단백질 활성효소 C의 방해 방법.
    식에서, R1과 R2는 독립적으로 H, 알킬, 아릴 또는 아릴알킬; m과 n은 독립적인 1,2 또는 3;X는 H, OH, NR3R4, Cl, Br, I, F, 알킬, 아릴 알콕시, 아록시, COOR5, 또는 CONR6R7;그리고 R3, R4, R5, R6및 R7은 독립적으로 H, 저가 알킬 또는 아릴인 것을 특징으로 하는 치환 안트라퀴논을 이용한 단백질 활성효소 C의 방해방법.
  12. 제11항에 있어서, R1과 R2는 독립적으로 H, 저가 알킬, 또는 아릴알킬; m과 n은 독립적으로 1 또는 2;X는 H, OH, Cl, Br, I, F, 알콕시인 것을 특징으로 하는 치환 안트라퀴논을 이용한 단백질 활성효소 C의 방해방법.
  13. 제12항에 있어서, R1과 R2는 독립적으로 H, 또는 아릴알킬; m과 n은 1;X는 H, 또는 OH인 것을 특징으로 하는 치환 안트라퀴논을 이용한 단백질 활성효소 C의 방해방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920701571A 1990-11-02 1991-10-30 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논 KR920703512A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60824890A 1990-11-02 1990-11-02
US608,248 1990-11-02
US07/609,416 US5141957A (en) 1990-11-02 1990-11-05 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US609,416 1990-11-05
PCT/US1991/008030 WO1992007558A1 (en) 1990-11-02 1991-10-30 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c

Publications (1)

Publication Number Publication Date
KR920703512A true KR920703512A (ko) 1992-12-18

Family

ID=27085707

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920701571A KR920703512A (ko) 1990-11-02 1991-10-30 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논

Country Status (11)

Country Link
US (1) US5141957A (ko)
EP (1) EP0509088A4 (ko)
JP (1) JPH05505829A (ko)
KR (1) KR920703512A (ko)
AU (1) AU641581B2 (ko)
BR (1) BR9106117A (ko)
CA (1) CA2072884A1 (ko)
FI (1) FI923031A0 (ko)
HU (1) HUT64296A (ko)
NO (1) NO922601L (ko)
WO (1) WO1992007558A1 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA936396B (en) * 1992-09-08 1994-06-13 Univ Vermont 4-Substituted 6,9-bis(substituted-amino)benzo[g] isoquinoline-5,10,diones
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
AU2771395A (en) * 1994-06-14 1996-01-05 Sloan-Kettering Institute For Cancer Research Ceramide-activated protein kinase and methods of use of effectors
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
IL140716A0 (en) * 1998-07-06 2002-02-10 Use of inhibitors of protein kinase c epsilon to treat pain
US6717030B2 (en) * 1998-07-06 2004-04-06 The Regents Of The University Of California Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
NZ574520A (en) 2002-11-27 2011-02-25 Dmi Biosciences Inc Use of casein which is at least 10% dephosphorylated for the treatment of diseases and conditions mediated by increased phosphorylation
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
CA2539132A1 (en) 2003-09-16 2005-03-24 Garvan Institute Of Medical Research Methods for identifying modulators of protein kinase c-epsilon (pkc.epsilon.) and method of treatment of aberrant glucose metabolism associated therewith
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
EP1940395A2 (en) 2005-09-16 2008-07-09 Schering Corporation Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
US8017583B2 (en) * 2007-01-19 2011-09-13 Kai Pharmaceuticals, Inc. Methods of use of epsilon inhibitor compounds for the attenuation of pain
EP2482837A4 (en) 2009-09-29 2013-05-22 Joslin Diabetes Center Inc USE OF INHIBITORS OF PROTEIN KINASE C DELTA (PKCD) FOR THE TREATMENT OF DIABETES, OBESITY AND HEPATIC STEATOSIS
AU2015256266B2 (en) 2014-05-05 2019-01-17 Emory University BH4 antagonists and methods related thereto

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1540733A (en) * 1923-10-25 1925-06-02 British Dyestuffs Corp Ltd Dyestuffs of the anthraquinone series
US2411148A (en) * 1943-10-23 1946-11-19 Eastman Kodak Co Anthraquinone dyestuffs
US3960751A (en) * 1973-09-19 1976-06-01 Matsushita Electric Industrial Co., Ltd. Electro-optical display element
US4197249A (en) * 1977-08-15 1980-04-08 American Cyanamid Company 1,4-Bis(substituted-amino)-5,8-dihydroxyanthraquinones and leuco bases thereof
US4310666A (en) * 1978-04-10 1982-01-12 United States Of America Anti-neoplastic 1,4-bis-(substituted aminoalkyl amino)-anthraquinones
US4526989A (en) * 1978-07-11 1985-07-02 American Cyanamid Company 1,4-Bis (substituted-amino)-5,8-dihydroxy-anthraquinones and leuco bases thereof
US4598155A (en) * 1981-11-18 1986-07-01 Ciba-Geigy Corporation 3(5-tetrazolyl)1,4-diaminoanthraquinones
US4540788A (en) * 1983-07-14 1985-09-10 American Cyanamid Company Schiff bases of [(aminoalkyl or substituted aminoalkyl)amino]-9,10-anthracenediones
DE3331296A1 (de) * 1983-08-31 1985-03-14 Hoechst Ag, 6230 Frankfurt Mono- und bisfunktionelle anthrachinon-(oxy-2,3-oxidopropane), verfahren zu ihrer herstellung und ihre verwendung
US4894451A (en) * 1985-04-01 1990-01-16 The University Of Vermont Unsymmetrical 1,4-bis(aminoalkylamino)-anthracene-9, 10-diones and derivatives
JPS6315853A (ja) * 1986-07-07 1988-01-22 Dainippon Printing Co Ltd 熱転写シ−ト用染料
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0219818A (ja) * 1988-07-07 1990-01-23 Nec Corp 暗視双眼鏡
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
GB8923075D0 (en) * 1989-10-13 1989-11-29 Patterson Laurence H Anti-cancer compounds
AU637014B2 (en) * 1990-11-02 1993-05-13 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase c

Also Published As

Publication number Publication date
HUT64296A (en) 1993-12-28
WO1992007558A1 (en) 1992-05-14
NO922601D0 (no) 1992-07-01
CA2072884A1 (en) 1992-05-03
NO922601L (no) 1992-07-01
EP0509088A1 (en) 1992-10-21
EP0509088A4 (en) 1993-03-24
AU641581B2 (en) 1993-09-23
HU9202207D0 (en) 1992-12-28
FI923031A (fi) 1992-06-30
JPH05505829A (ja) 1993-08-26
BR9106117A (pt) 1993-03-09
FI923031A0 (fi) 1992-06-30
US5141957A (en) 1992-08-25
AU9086291A (en) 1992-05-26

Similar Documents

Publication Publication Date Title
KR920703512A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 1, 4-비스-(아미노-하이드록시알킬아미노)-안트라퀴논
NO933482L (no) N-sulfonyl-2-oksoindol-derivater som har affinitet for vasopressin- og/eller ocytocin-reseptorer
KR920018029A (ko) 신규한 카복실산 아미드
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
KR890701557A (ko) 리폭시게나제 억제화합물을 함유하는 푸란 및 피롤
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
KR870003974A (ko) 비시클로 치환된 페닐아세토니트릴 유도체
ES2108129T3 (es) Nuevos derivados de pirazina, su preparacion y empleo.
KR960007592A (ko) 신규한 피롤로카바졸
KR920703513A (ko) 단백질 활성효소 c(protein kinase c)를 방해하는 비스-(하이드록시알킬아미노)-안트라퀴논
IL96636A0 (en) Piperidine derivatives and pharmaceutical compositions containing them
KR890009962A (ko) 매뉴마이신 유도체, 이의 제조방법 및 용도
KR900018048A (ko) 환 치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌
KR950016735A (ko) 터너 증후군의 억제 방법
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
KR900003177A (ko) 테트라시클릭계 우울증 치료제
KR880011112A (ko) 벤즈아제핀 설폰아미드 화합물
KR890006639A (ko) 벤조티아진 디옥사이드 유도체
KR910004557A (ko) 2,4,6-치환 페놀 유도체
KR920007995A (ko) 벤즈아미드 유도체
KR900701795A (ko) 티에노시클로 헵타피리다진 화합물과 그것의 의약용도
KR910005860A (ko) 항간질환성 조성물
HUT70761A (en) Alkyl derivatives of trazodone having action for central nervous system, pharmaceutical compositions for preparing thereof
KR850000415A (ko) 퀴나졸리논 유도체의 제조방법
KR890006231A (ko) 상승작용을 하는 안내압 저하 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application